This week, the financing heat in the medical and health field has risen, covering cutting-edge tracks such as tumor immunity, nuclear drugs, brain computer interfaces, and synthetic biology. Fosun Pharma leads the way in IO2.0 cytokine therapy, while Crystal Nucleus Biotech has invested nearly 400 million yuan in targeted nuclear drugs. Brain Think Technology and Ruiyi Xulian are shining in the first year of brain computer interface, and the acquisition of 1.5 billion yuan by Weiyuan Synthesis is driving the upgrading of biomanufacturing. Capital is accelerating its gathering towards hard tech enterprises with underlying technological breakthroughs and clinical scarcity value, demonstrating the strong vitality of the medical innovation ecosystem.

---

1、 IO2.0 cytokine therapy leader Fosun Pharma completes first round of Pre-B financing

Recently, Suzhou Furong Biotechnology Co., Ltd. announced on its seventh anniversary that it has completed the first round of nearly RMB 100 million in Pre-B financing. This round of financing is led by Fudan Science and Technology Innovation Fund, with joint investment from Changshu Guofa Venture Capital and Suzhou Hanwu Venture Capital.

At present, tumor immunotherapy (IO) has entered the 2.0 innovation stage, and engineered cytokines have become the most popular sub track in the treatment of refractory solid tumors due to their unique mechanism of effectively activating innate immunity and overcoming PD-1 inhibitor resistance. Multiple products worldwide have entered the late stage of clinical validation, and China has also entered a critical period of clinical translation. Fosun Pharma has built an internationally leading integrated synthetic immune technology system driven by synthetic immunology, targeting the industry pain points of short half-life, high systemic toxicity, and insufficient targeting of traditional cytokines. The technical barriers are clear, and the pipeline layout is significantly differentiated.

The company’s first pipeline FL115 is an engineered IL-15/IL15R α – Fbody fusion protein, which has completed early clinical trials. Published data shows that it has good systemic exposure and safety, and preliminary anti-tumor responses have been observed in various refractory solid tumors, with the potential for “best in class”; The second candidate drug FL116 is a new generation of engineered cytokines, which has been validated in preclinical studies to have potent tumor killing activity and a wider safety window.

The core of this financing will be used to promote the registration of FL115 in clinical research, accelerate the completion of IND application and clinical development of FL116, and simultaneously improve the technology platform upgrade and subsequent pipeline reserve. The investors stated that as a leading enterprise in the domestic cytokine field, Fosun Pharma has clear advantages in technology transformation and pipeline progress, and outstanding long-term clinical value. (398 words in total)

---

2、 Tengdi Biotechnology, a new cyclic peptide drug company, has completed a $7.5 million Seed+round of financing to promote the construction of innovative drugs

Recently, Tengdi Biotechnology, which focuses on innovative cyclic peptide drug discovery, has completed a $7.5 million Seed+round of financing. This round is led by industry strategic investors and backed by a London based venture capital fund specializing in life sciences.

As an emerging drug molecule type that fills the gap in the advantages of small molecule drugs and large molecule antibody drugs, cyclic peptides have become a popular direction for developing difficult to develop drug targets in the global innovative drug field due to their high affinity, high selectivity, good tissue penetration, and drug potential. The core competitiveness of Tengdi Biotechnology comes from its independently built high-throughput cyclic peptide drug discovery and optimization technology platform, which can quickly screen and obtain targeted candidate molecules from a large capacity cyclic peptide molecular library. Currently, potential lead molecules in multiple pipelines have completed in vivo concept validation, obtained positive pharmacological data, and the maturity of the platform technology has been preliminarily verified. In recent years, milestone progress has been achieved in platform iteration and industry cooperation.

The funds from this round of financing will be directed towards three core directions: firstly, to strengthen the technological capabilities of the high-throughput cyclic peptide discovery platform, with a focus on promoting the integration of AI technology into the entire process of cyclic peptide molecule design, screening, and drug optimization, and systematically improving research and development efficiency; Secondly, we will promote the construction of multiple internal innovation pipelines targeting difficult to develop drug targets; The third is to expand industrial cooperation and provide high-quality targeted lead molecules for partners.

Tengdi Biotechnology founder Zhu Mingdao stated that this round of financing will accelerate the integration of AI and cyclic peptide research and development, and all investors are optimistic about the value and development path of the company’s differentiated platform. After the financing is completed, the company will adhere to the dual wheel drive strategy of “platform cooperation empowerment+independent pipeline promotion”, and build a globally competitive cyclic peptide innovative drug research and development enterprise.

---

3、 Shengzhi Medical has completed tens of millions of yuan in Series A financing, promoting the layout of the innovation ecosystem

Recently, Shanghai Shengzhi Medical Technology Co., Ltd., a local innovative equipment company focusing on the grand surgery track, announced to complete a round of financing of tens of millions of yuan. This round of financing was led by Enron Venture Capital, followed by the old shareholder Fengyu Capital. The funds will be used for the expansion of R&D and production bases, commercial promotion, as well as overseas layout such as FDA and CE certification, supporting the landing and global expansion of the company’s product matrix.

Shengzhi Medical was founded in 2020, anchoring the blank track of domestic substitution for high-end surgical instruments. It has established a clear gradient product pipeline and currently has two exclusive innovative products commercialized. Its core differentiation advantages are prominent: its “Zhishui” electrode breaks the long-standing naming monopoly of European and American giants on domestic centralized procurement categories and reconstructs the domestic competition rules for segmented categories; The “Zhirou” disposable stapler has broken through the technological monopoly of imported surgical robots in the field of suture reconstruction, solving the major pain points of difficult clinical operation, unstable anastomosis quality, and high medical costs. Currently, it has completed the nationwide consumables network, obtained multiple invention patents and US FDA approval qualifications, and its commercialization progress meets expectations.

Pipeline advancement display, the company expects to release the “Zhirou” monopolar electric hook in the second half of 2026, and the first disposable handheld portable surgical robot “Zhibao” has completed research and development, successfully completing its first animal experiment. The investment director of Enran Venture Capital stated that the current wave of domestic substitution for high-end surgical instruments is clear, and the ability of Shengzhi Medical to create differentiated products based on underlying original technology is in line with the industry’s innovation direction. We look forward to its product advantages to serve global patients.

---

4、 Jinghe Biotechnology has completed nearly 400 million yuan in Series B financing, leading the innovation of targeted nuclear drugs in China

Recently, Jinghe Biotechnology, which focuses on the development of integrated visualization diagnosis and treatment targeted radionuclide therapy, announced the completion of nearly 400 million yuan in Series B financing. This round of financing is jointly led by Pudong Venture Capital, Zhangjiang Science and Technology Investment, and IDG Capital, with old shareholder Gao Rong Venture Capital and other institutions joining in.

As one of the fastest-growing sub sectors in the field of precision diagnosis and treatment of tumors, targeted nuclear drugs have become a core hotspot for global innovative drug research and investment due to their unique advantages of strong tumor targeting, clear cell killing effects, and synchronous diagnosis and treatment. Jinghe Biotechnology relies on its independently controllable full chain targeted nuclear drug research and development platform, with pipeline layout covering high-risk and pan tumor fields with urgent clinical needs. The core pipeline JH02 benchmarks mature benchmark products overseas, and with its independently optimized molecular design, it is expected to achieve import substitution and fill the gap in domestic targeted nuclear drug products; The multi indication pan tumor pipeline JH04 has officially launched Phase I/II clinical research, and its overall progress ranks among the top in China.

The funds raised in this round of financing will be directed towards the clinical promotion of core pipelines, iterative upgrading of technology platforms, and preparation for global application layout. Yu Haihua, the founder of Jinghe Biotech, said that this round of financing will help the company’s core pipelines participate in the global competition of targeted nuclear drugs. The investors believe that the research and development capabilities and differentiated pipeline layout of Jinghe Biotechnology are in line with the industry development trend, and are expected to grow into a leading enterprise in the field of targeted nuclear drugs in China, promoting industry innovation breakthroughs and benefiting global cancer patients.

---

5、 BrainThink Technology has completed an angel round financing of over 10 million US dollars, accelerating the development of brain computer interfaces

Recently, Brain Computer Interface Medical Innovation Enterprise Brain Think Technology announced the completion of a series of angel round financing of over 10 million US dollars. This financing was led by Kangjun Capital and Lanchi Venture Capital, with Rehabilitation Capital following suit. The core of this round of funds will be used for product engineering implementation, iterative development of neural based models, and optimization of full stack electrode processes, promoting the commercialization of core technologies.

This project is led by Professor Chen Guoliang from the University of Hong Kong, and was established based on a world-class neuroscience research platform. It has built a “Shenzhen Hong Kong Collaborative” dual R&D system and has completed early validation of core technologies, achieving phased R&D breakthroughs. Different from most entrepreneurial entities in the field that focus solely on hardware or algorithms, BrainThink Technology has established a complete technical chain from electrode design, chip development to algorithm models. It has an independent and controllable full stack electrode research and development system, and is also the first to lay out neural specific basic models, creating an integrated product solution of “hardware+AI”.

The current global brain computer interface industry has entered the eve of industrialization, and the industry has formed a consensus to regard 2026 as the first year of commercialization of brain computer interfaces. The first generation of products from BrainThink Technology focuses on two essential medical scenarios: “Mind Voice Recovery” and “Exoskeleton Mind Control”, accurately covering the clinical needs of neurological dysfunction groups such as ALS and spinal cord injury. It will gradually expand its application scenarios in the future. The investors stated that the scientific research accumulation and full stack layout of BrainThink Technology are in line with the industrialization development direction of the track, and they are very optimistic about its technology transformation prospects. The company founder also stated that they will continue to promote the brain computer interface technology from the laboratory to the daily application of the public.

---

6、 Peanut Health has completed a new round of financing and upgraded to an AI driven platform for managing the entire lifecycle of both genders

The domestic AI driven full life cycle health management track for both genders has ushered in a key capital injection. Recently, Peanut Health officially announced the completion of a new round of financing, with investors including PwC Capital, Xiaochi Fund, and multiple industry and professional financial investment institutions such as Jiaxing Xinyi.

Peanut Health, founded in 2014, focuses on reproductive medicine and has offline layout. Currently, it has established compliant medical institutions in multiple provinces and cities, accumulating clinical medical records, diagnosis and treatment behavior data, and professional physician resources of millions of users. It has built a complete business foundation of offline medical scenarios and online digital operations in advance. In 2019, the company launched its independently developed “Peanut Cloud” intelligent system, which deeply integrates AI technology into the entire process of customer acquisition, diagnosis and treatment, and management. After achieving scale commercialization, the company has maintained a doubling of revenue growth for six consecutive years, with non-medical insurance income accounting for over 99%, demonstrating strong self generating ability. The performance guidance shows that the company expects its revenue to exceed 1 billion yuan by 2026.

After this round of financing, Peanut Health has launched a strategic upgrade, benchmarking against the global leading D2C gender health brand Hims and Hers, positioning itself as an AI driven digital health management platform for the entire lifecycle of both sexes. In the future, it will focus on expanding its product line for gender specific diseases across the entire spectrum, while also laying out cutting-edge research and development for reproductive organs and building technological barriers. Xiaochi Fund stated that Peanut Health has achieved a commercial closed loop of “offline diagnosis and treatment customer acquisition+AI efficiency improvement+high gross profit self funded services”, and the industry has outstanding growth potential. It is reported that Peanut Health has officially launched preparations for its IPO on the Hong Kong stock market in 2025.

---

7、 Xinyu Biotechnology has completed a multi million yuan angel round of financing, accelerating the layout of its life science toolchain

Xinyue Biotechnology, a subsidiary of Zhongxin Biotechnology that focuses on the development of life science underlying tools, recently announced the completion of a multi million yuan angel round of financing. The investor in this round is the Hunan Provincial College Student Entrepreneurship Investment Fund, which was jointly established under the guidance of Hunan Province. The funds raised will be mainly used for the research and development iteration of the core equipment of black light photoelectric tweezers, the expansion of the core technology team, and the initial market commercialization promotion.

With the rapid industrialization of fields such as single-cell omics, cell therapy, and synthetic biology, the demand for high-precision single-cell screening equipment in the global life science field continues to rise. However, the domestic high-end single-cell operation equipment market has long been monopolized by overseas manufacturers, and there is an urgent need for domestic substitution with vast market space. Founded in 2024, Xinyu Biotechnology has a core team covering interdisciplinary fields such as optics, biomedical science, and automation. The black light optoelectronic tweezers system, which is focused on layout, can achieve non-contact single-cell precise control and has high-throughput automated screening capabilities. It can significantly reduce downstream research and development costs and cover various life science research and industrial application scenarios.

At present, the domestic optoelectronic tweezers tool market is still in the early stages of development, with sufficient space for substitution. The first research version of the black light optoelectronic tweezers equipment by Xinyu Biology has been commercialized and put on sale. The founder of Xinyu Biotechnology stated that the team’s goal is to promote the use of optoelectronic tweezers as a universal infrastructure for life science laboratories, and the domestic alternative direction has also been highly recognized by investors. This financing will further accelerate the localization layout of the company’s life science tool chain.

---

8、 Dage Biotechnology has completed a $40 million Series A expansion financing to advance the clinical development of molecular gel degradation agents

Recently, innovative drug company Dage Biotechnology in the field of targeted protein degradation announced the completion of a $40 million Series A expansion financing. This round is led by Longpan Capital, with multiple professional investment institutions following suit, and Haoyue Capital serving as the exclusive financial advisor. The company’s cumulative financing amount has reached $95 million.

Molecular gel degradation agents are currently the core cutting-edge technology direction for breaking through the limitations of “non pharmaceutical” targets, and global research and development investment and industrial layout continue to accelerate. Dage Biotechnology was founded by senior drug development expert Cang Haoxin in 2021, focusing on innovative development of molecular gel degradation agents at the source. We have independently built a GlueXplorer that covers the entire process of target validation, molecular screening, and drug efficacy optimization ® The discovery platform has built a diverse molecular gel compound library with a scale of over 10000 species. It has previously reached a target development cooperation with Takeda Pharmaceuticals, and the platform’s technical capabilities have been verified by the industry.

The core of this round of financing is used to promote the clinical development of the company’s core pipeline DEG6498: this pipeline is a global First in Class HuR molecular gel degrader – HuR is a key hub for regulating the expression of various oncogenic and pro-inflammatory factors, and belongs to the classic difficult to target targets. Currently, DEG6498 has entered phase I clinical dose escalation research and is one of the few self-developed molecular gel projects in China that has entered the clinical stage.

In addition, the funds will be used to promote the development of early immunology pipelines and expand platform technology capabilities to incubate more differentiated candidate drugs. The leading investor expressed optimism about Dage’s research and development capabilities and the long-term commercialization potential of the molecular gel track. This financing also reflects the capital’s recognition of the value of the top projects in the clinical realization period of the domestic protein degradation track.

---

9、 Ruiyi Xulian has received nearly 100 million yuan in Pre-A round financing, accelerating the clinical progress of implantable brain computer interfaces

Recently, Ruiyi Xulian, which focuses on the field of neuromedical devices, announced the completion of nearly 100 million yuan in Pre-A round financing. This round of financing is jointly led by Nuoyu Capital and Weili Medical, with multiple industry and financial investment institutions following suit. The old shareholders have overpaid, and Hornet Capital serves as the exclusive financial advisor.

As a cutting-edge technology in the field of implantable brain computer interfaces in China, Ruiyi Xulian was established in March 2024, targeting major brain diseases such as epilepsy and neurodegenerative diseases that have huge unmet clinical needs. It has built a full stack core technology barrier covering invasive electrode research and development, neural signal decoding, and closed-loop stimulation system development, with outstanding technological autonomy and system integration capabilities.

The company’s pipeline layout gradient is clear: the core high-value product “Brain Spine Interface” has entered the stage of mass production preparation and clinical research. The company expects that this product is expected to be approved for NMPA Class III medical device registration certificate in 2028; The NeuroPulse portable four channel electrical stimulation therapy device, which has been launched in compliance with regulations, has achieved commercialization and sales have steadily increased since its launch; At the same time, the company is forward-looking in the layout of wearable consumer grade brain computer interface products, covering multiple scenarios of medical and consumer needs.

The funds from this round of financing will be fully used to promote the implementation of implantable bidirectional brain computer interface technology, accelerate the clinical research process and mass production transformation of the core product “Brain Spinal Interface”. The investors stated that the global brain computer interface industry has entered a critical period of commercialization breakthrough. Ruiyi Xulian’s clear pipeline planning and rapid landing capability are in line with the industry development trend, and they look forward to its products benefiting millions of domestic brain disease patients as soon as possible.

---

10、 Weiyuan Synthesis raises 1.5 billion yuan to acquire Yuxin, promoting the upgrading of biomanufacturing in the sugar alcohol industry

Recently, the biomanufacturing enterprise Weiyuan Synthesis announced the completion of a new round of financing worth 1.5 billion yuan. This round of financing consists of equity financing and long-term bank loans provided by Industrial Bank Beijing Branch. The funds will be specifically used for the acquisition of Yuxin Sugar Alcohol, the world’s second-largest xylitol producer, and the large-scale production and landing of core sugar alcohol products.

As a leading enterprise in the global sugar and alcohol industry, Yuxin has a mature production capacity of hundreds of thousands of tons, a complete supply chain system, and a senior production and operation team, with outstanding advantages in large-scale production implementation. The current global sugar and alcohol industry is still dominated by chemical synthesis processes, and traditional routes generally suffer from pain points such as high comprehensive costs, difficulty in handling by-products, and large fluctuations in agricultural and forestry raw material supply. The demand for green upgrading of the industry is urgent.

Weiyuan Synthesis has the world’s first sugar alcohol synthesis bio production technology empowered by AI bio computing platform, which achieves efficient preparation of sugar alcohols through precise fermentation pathways and significantly reduces overall production costs; This process uses starch sugar as raw material, which eliminates the dependence of traditional processes on agricultural and forestry by-products such as corn cobs. It has a large space for capacity expansion and has the advantages of low pollution, low energy consumption, and high product purity. It can promote the transformation and upgrading of the sugar alcohol industry from chemical methods to biomanufacturing.

The equity investors in this round include industry investors Zhang Qibin, Tan Ruiqing, and institutional Xingyin Investment. The industry believes that the industry finance integration model of “technology empowerment+mature production capacity mergers and acquisitions” is a benchmark case for synthetic biology to connect from laboratory to large-scale commercialization, which will accelerate the substitution and upgrading of traditional chemical industry by biomanufacturing.

---

11、 Yiminokang completes 250 million yuan Series A financing to accelerate the construction of a human antibody discovery platform

Recently, Shanghai Yiminokang Biotechnology Co., Ltd., a domestic innovation antibody discovery platform enterprise, officially announced the completion of a 250 million yuan Series A financing. This round of financing is led by Weiwu Capital and followed by Gaomai Yuanhang. All existing shareholders have completed excess additional investment, highlighting the recognition of capital.

Established in 2020, Yiminokang is positioned as a technology driven platform based biotechnology company. Its core direction is to build the next generation of fully humanized antibody discovery system based on gene editing technology, solving industry pain points such as insufficient humanization, long development cycle, and low affinity in the traditional antibody discovery process. The company’s core independent intellectual property MASIRT ® The technology has achieved triple core technological breakthroughs, with better performance than traditional transgenic antibody discovery platforms; At present, a gene editing model animal platform covering multiple species such as rabbits and mice has been established, and the global intellectual property layout has been completed, building a deep technological barrier. At the same time, the company independently promotes MabAI ® The construction of an AI assisted antibody discovery platform has been validated by the industry, and its technological maturity has been verified. Currently, it has established research and development cooperation with several leading domestic pharmaceutical companies.

The funds raised in this round of financing will mainly be used for three core directions: research and development iteration of gene edited animal platforms MASIRT ® Commercial implementation of the all human antibody rabbit platform MabAI ® The construction and improvement of AI assisted antibody screening platform. The founder of Yiminokang stated that this round of financing will accelerate the company’s platform capability upgrade and independent innovation pipeline layout. Investors also generally believe in the company’s differentiated technological advantages and global competitiveness, as well as its infrastructure value in the domestic innovative antibody drug research and development system.

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.